Lifecore stock reaffirmed at Equal Weight at Stephens following Q2 results

Published 03/01/2025, 15:24
Lifecore stock reaffirmed at Equal Weight at Stephens following Q2 results

On Friday, Stephens analysts maintained an Equal Weight rating on Lifecore Biomedical (NASDAQ:LFCR) following the company's reported revenue and adjusted EBITDA beat for the second quarter of fiscal year 2025. Lifecore Biomedical's revenues saw approximately an 8% year-over-year increase, fueled by a $3.8 million rise in revenue from the company's largest customer.

This growth was slightly offset by a $1.9 million decline in revenue from other Contract Development and Manufacturing Organization (CDMO) customers. Additionally, hyaluronic acid (HA) revenues increased by $0.5 million year-over-year, attributed to the timing of customer shipments.

During the second quarter, Lifecore Biomedical signed two new project agreements, which are expected to bolster their early stage development pipeline. The company's gross margins reached 34.0%, surpassing the 28.5% estimate and contributing to the adjusted EBITDA outperformance. The firm's operational expenditure control also played a role in exceeding financial expectations. Despite these positive outcomes, Lifecore Biomedical's stock experienced a sell-off of approximately 10% today.

Stephens analysts have reiterated their Equal Weight-Volatile rating for Lifecore Biomedical, indicating a neutral stance on the stock's investment potential. The company's financial guidance for the full fiscal year 2025 remains unchanged. The analysts are currently reviewing their estimates and price target for Lifecore Biomedical following the recent financial results.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.